Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of an exclusive generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%, in the US.
Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.
With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in six generic prescriptions dispensed in the US is filled with a Teva product. Teva is committed to strengthening its generics business through continued investment in complex, high-quality products.
"Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio," said Dipankar Bhattacharjee, Teva’s President and CEO, Global Generic Medicines. "This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market." Pataday had annual sales of a $303 million in the US, according to IMS data as of March 2017.
Published by Globes [online], Israel business news - www.globes-online.com - on June 11, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017